The use of ticagrelor in acute coronary syndrome (ACS) patients who underwent percutaneous coronary intervention appears to reduce the risk of major adverse cardiovascular and cerebrovascular events (MACCE) without increasing major bleeding episodes when compared with clopidogrel, although the former antiplatelet strategy may heighten the risk of minor bleeding, according to a study.
While adding varenicline to weekly counselling for smoking cessation did not improve abstinence rates among adolescent smokers at the end of treatment, it may promote earlier abstinence and sustained response to varenicline post-treatment, a study finds.
Concurrent chemoradiotherapy (CCRT) appeared to improve survival rates in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), according to a systematic review and meta-analysis, with a potential benefit noted with the addition of induction chemotherapy.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.
Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The oral multikinase VEGFR*1, 2, and 3 inhibitor pazopanib failed to improve overall survival (OS) in advanced ovarian cancer patients who have not progressed following first-line chemotherapy, according to the results of the AGO-OVAR16** study.
The combination of gemcitabine plus S-1 (GS) is as good as gemcitabine plus cisplatin (GC), the current standard treatment for advanced biliary tract cancer (BTC), according to data from the phase III FUGA-BT trial (JCOG1113). However, the former does not require concomitant hydration therapy and should be considered a new treatment option for patients with advanced or recurrent BTC.
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.
Use of diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID) with cyclo-oxygenase-2 (COX-2) selectivity similar to COX-2 inhibitors, is associated with higher cardiovascular health risk compared with nonuse, paracetamol use and use of other traditional NSAIDs, a recent study has shown.